The management of cancer pain presents manifold challenges: Even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering / Romualdi, Patrizia; Candeletti, Sanzio. - In: MINERVA MEDICA. - ISSN 0026-4806. - STAMPA. - 107:2(2016), pp. 114-122.
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering
ROMUALDI, PATRIZIA;CANDELETTI, SANZIO
2016
Abstract
The management of cancer pain presents manifold challenges: Even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.